SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Alexion Pharmaceuticals, Inc. (ALXN)
An SI Board Since October 1997
Posts SubjectMarks Bans Symbol
824 29 0 ALXN
Emcee:  Larry Liebman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
249Fingers crossed is all that is reasonable at this point. Cautious is prudent apkeokalani'nui-11/15/2002
248WE, I am keeping my fingers crossed. It is not secret that I was cautious on MIMiljenko Zuanic-11/15/2002
247Depends on what "it" is. "It" means big deal to me because keokalani'nui-11/15/2002
246Wilder It's only phase II. Do you really think it will make much differenceIcebrg-11/15/2002
245AHA Monday. Plenary session on pexi in MI at 10:45, late breaker. CC after markeokalani'nui-11/15/2002
244OT, (this should be discussed at MLNM tread): WE, <<My notes say trial oMiljenko Zuanic-11/7/2002
243My notes say trial originally planned for 74 but was expanded to 202 so there shkeokalani'nui-11/7/2002
242Paraprotein level response and major response are not the some. However paraprotMiljenko Zuanic-11/6/2002
241alxn data is very strong. But 10 P1 patients might represent the universe in thkeokalani'nui-11/6/2002
240ASH abstracts are available . . . >>[154] Eculizumab, a C5 Complement–tuck-11/6/2002
239Thanks!keokalani'nui-11/4/2002
238ALXN gets an honorable mention near the end of this article... msnbc.comIan@SI-11/4/2002
237So company will have to burn another 4 years and $150M before knowing if 5g1.1 ikeokalani'nui-11/4/2002
236So pts will have to take more Eculizumab for much longer periods of time. SoundIan@SI-11/4/2002
235Alexion Reports Presentation of Membranous Nephritis Clinical Trials Monday Novekeokalani'nui-11/4/2002
234November 3 ASN: P2 IMN, 117 patients. 5g1.1 November 18 AHA (late breaker): keokalani'nui-10/31/2002
233Not encouraging price volume behavior today. Chart now looks like yucky news is keokalani'nui-10/22/2002
232Prelim PK/PD MN abstract (a bookmark, more accurately) at Nov nephrology conf. keokalani'nui-10/19/2002
231500k at $12.85. Unless they meant cisco. (eom) Looks more like unload than loakeokalani'nui-10/7/2002
230LOL. Alimentary, my dear Wilder.nigel bates-10/3/2002
229Shhh. This puppy wants up. Looks like it is entering the large intestin configukeokalani'nui-10/3/2002
228Thanks, Biomaven. Not much new there, but a 8,000+ patient study from this centkeokalani'nui-9/4/2002
227Big study of CK-MB elevation in PCI patients with compelling results: <i>Biomaven-9/4/2002
226Neurogen has been very quiet with its program. Not sure I see the benefit of ankeokalani'nui-8/30/2002
225Note that Neurogen has an active small molecule C5a antagonist program: neurogeBiomaven-8/30/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News